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ABSTRACT
Kinases such as MEK are attractive targets for novel therapy in cancer, including 
acute myeloid leukaemia (AML). Acquired and inherent resistance to kinase inhibitors, 
however, is becoming an increasingly important challenge for the clinical success 
of such therapeutics, and often arises from mutations in the drug-binding domain 
of the target kinase. To identify possible causes of resistance to MEK inhibition, we 
generated a model of resistance by long-term treatment of AML cells with AZD6244 
(selumetinib). Remarkably, resistance to MEK inhibition was due to acquired PTEN 
haploinsufficiency, rather than mutation of MEK. Resistance via this mechanism was 
confirmed using CRISPR/Cas9 technology targeting exon 5 of PTEN. While PTEN loss 
has been previously implicated in resistance to a number of other therapeutic agents, 
this is the first time that it has been shown directly and in AML.
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INTRODUCTION
Pediatric acute myeloid leukemia (AML) causes 
a disproportionate number of childhood cancer deaths 
[1, 2]. The peak incidence of childhood AML occurs in 
children under 4 years (1.1 per 100,000; 1982–2007) 
[2, 3]. The event-free survival for childhood AML is only 
50 to 60% despite complete remissions being achieved 
in approximately 90% of children with front-line therapy 
[4]. Furthermore, improvements in overall survival for 
childhood AML over the past 30 years can be largely 
attributed to more intensive use of conventional cytotoxics 
and improved supportive care [5]. Conventional therapy for 
pediatric AML parallels strategies that have been used in 
adults and is based on intensive use of cytarabine (cytosine 
arabinoside, Ara-C), etoposide and anthracyclines [6]. 
For relapsed patients, most therapeutic regimens include 
further cytarabine in combination with other agents [7]. 
The effectiveness of chemotherapy is limited by not only 
acute toxicity, but also late effects such as an increased risk 
of secondary malignancy and cardiotoxicity [8, 9]. These 
chemotherapy-associated side effects are of particular 
concern in children given that treatment occurs during 
growth and development. Therefore, there is a desperate 
need for more efficacious, yet less toxic, therapeutic 
strategies to improve outcomes for pediatric AML patients.
Substantial evidence supports an essential role of 
Ras/Raf/MEK/ERK1/2 kinases in tumourigenesis [10]. 
Constitutive activity of the Ras/Raf/MEK/ERK1/2 signaling 
cascade has been reported in a wide variety of liquid and 
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solid cancer types including AML, acute lymphoblastic 
leukemia (ALL), breast, melanoma and prostate cancer 
[11]. Inappropriate or prolonged activation of the Ras/
Raf/MEK/ERK1/2 pathway have been suspected to lead 
to altered gene expression and contribute to cancer and 
chemotherapy resistance [12]. Therefore, small molecule 
inhibition of kinases within the pathway, such as MEK, has 
been investigated for their therapeutic potential [13, 14].
Several MEK inhibitors have shown promising 
pre-clinical activity in adult AML, with a number of 
compounds currently being evaluated in phase I/II clinical 
trials, including MEK162, GSK1120212 and AS703026 
[15–19]. However, the frequent development of resistance 
to kinase inhibitors, such as imatinib and sorafenib, 
through a variety of mechanisms such as acquisition of 
additional mutations within the kinase domains of the 
target proteins, leads us to an important question: will 
MEK inhibitor utility in AML be limited by rapid selection 
and expansion of subclones that either express or develop 
intrinsically resistant mutations in the pathway or that lack 
dependence on MEK signaling for growth and survival? 
To answer this question, we established an in vitro model 
of MEK inhibitor resistance using THP-1 cells, incubated 
in increasing concentrations of selumetinib (clinical trial 
NCT00588809; completed), to identify the mechanism (s) 
that may lead to resistance in AML patients. We identified a 
partial deletion of the tumour suppressor phosphatase and 
tensin homolog (PTEN) as a clinically relevant genomic 
alteration in 100% of replicate resistance cell lines that 
we developed. We also confirmed that disruption of the 
PTEN catalytic core motif domain was the mechanism of 
resistance using CRISPR-mediated deletion of PTEN exon 
5, a region which contributes to the catalytic activity of 
this tumour suppressor [20]. Given the observation that 
PTEN deletion is a mechanism for MEKi resistance in 
solid tumours [21, 22], and that deletion of PTEN in AML 
is sufficient to confer resistance, we propose that this event 
can be used as a biomarker of MEK inhibitor resistance in 
AML. This is also the first report of PTEN deletion as a 
mechanism of small molecule inhibitor resistance in AML.
RESULTS
MEK inhibitors reduce proliferation in AML 
cells in vitro
There is a considerable amount of in vitro, in vivo 
and clinical data investigating the utility of MEK inhibitors 
to treat adult AML [13, 14]. However, it is not known if 
MEK inhibitors are efficacious in treating pediatric AML. 
Therefore, we firstly interrogated whether pediatric AML-
derived cell lines were sensitive to MEK inhibitors in 
vitro. We used a panel of seven MEK inhibitors and tested 
them in 11 cell lines including six pediatric and five adult 
AMLs encompassing the most prevalent cytogenetic and 
molecular features found in patients. We found varying 
sensitivity across all compounds tested in a proliferation 
assay. However, the majority exhibited nanomolar IC50s 
across most cell lines (Table 1). Interestingly, one pediatric 
AML cell line CMK and one adult AML cell line HEL 
showed overt resistance to MEK inhibitors suggesting an 
intrinsic resistance that does not require drug exposure or 
selection pressure to develop.
Previous studies have shown that the MEKi 
PD0325901 can inhibit cell cycle progression in the OCI-
AML3 cell line [23] and GSK1120212 induces cytostatic, 
rather than cytotoxic, effects in particular cytogenetic 
backgrounds in a variety of cancer cell lines [16]. Therefore, 
it is possible that MEKi-associated anti-proliferative effects 
observed in Table 1 are a consequence of MEKi-induced 
cell cycle arrest. To test this hypothesis, we interrogated cell 
cycles in the AML cells after a 96 h treatment with MEKi 
(0.01, 0.1, 1 µM) (Supplementary Figure 1). We observed a 
range of cell cycle responses, with most cell lines exhibiting 
reduced S/G2/M populations in response to MEKi.
MEKi synergize with chemotherapeutic 
compounds
The basis for poor clinical response in AML patients 
is attributed to the development of resistance to current 
chemotherapeutic protocols. One mechanism of resistance is 
thought to be due to hyperactivation of the MAPK signalling 
pathway owing to the production of reactive oxygen 
species, a by-product of chemotherapy [11]. Therefore, we 
hypothesized that inhibition of MAPK signalling in addition 
to treatment with chemotherapy would sensitize cells to 
death and potentially prevent the development of resistance. 
To investigate the potential for synergistic therapeutic effect 
between MEKi and the chemotherapeutic compounds 
Ara-C, etoposide and daunorubicin, four pediatric AML 
cell lines were co-treated for 96 h at fixed drug ratios (Table 
2). The combination index (CI; quantitative measure of the 
extent of drug interaction) was calculated for the ED50 
(effective dose) using Chou-Talalay analysis [24]. AZD6244 
was the most synergistic when combined with all cytotoxics 
examined across all four cell lines with ED50 CI of <0.01-
0.96. Combinations with other MEKi were variable (Table 
2). However, it appeared that etoposide in combination with 
MEKi trended towards antagonism (>1.1). Interestingly, 
co-treatment of CMK cells (which are overtly resistant to 
MEKi monotherapy) with either cytarabine or daunorubicin 
sensitized the cells to the inhibition of proliferation. These 
data suggest that combination therapy of MEKi with 
cytotoxics that are currently in use clinically for pediatric 
AML is a potential strategy to sensitize AML cells to growth 
inhibition and cell death, even in the cells that are resistant 
to MEKi monotherapy.
Acquired PTEN haploinsufficiency contributes to 
MEKi resistance
Resistance to small molecule inhibitors is a 
recognized clinical problem across a range of cancers. 
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It has become evident that surveillance for resistance 
is imperative to detect early relapse in patients and 
understanding the mechanisms and biomarkers for 
resistance is key. Therefore, we developed eight THP-1 
cell lines independently derived to have resistance against 
AZD6244, subsequently referred to as TR, to investigate 
the how cells acquire resistance to MEKi.
We hypothesized that TR cells acquired somatic 
mutations in MEK-related genes which contribute to 
MEKi resistance [25]. In order to characterize these 
acquired mutations, we performed targeted exome 
sequencing on THP-1 cells grown in culture with DMSO 
only (control) (n=8) and on the TR (n=8) cells. A total 
of 239 single nucleotide variants (SNVs) were identified 
(Supplementary File 1). However, no SNVs were recurrent 
across all resistant lines suggesting they were not the 
drivers of resistance. The most commonly occurring SNV 
was a missense mutation in NTRK2 (chr9:87570296, in 4 
of 8 resistant lines) (Supplementary Figure 2). However, 
the low variant allele frequencies (range: 12%-19%) 
suggest that this mutation is likely subclonal and does not 
contribute significantly to MEKi resistance. In contrast 
to small number of SNVs, copy number changes were 
found in 835 genes including a single, clonal copy loss of 
PTEN in all 8 resistant samples (Supplementary File 2). 
We also observed subclonal copy gain of KRAS in all 8 
samples, as well as subclonal copy loss of both ELOVL2 
and IRF4 (Figure 1), all of which have been identified 
in tumours although the effect of these copy number 
losses in AML is unknown. Interestingly, PTEN exons 
appeared to be affected differently. For example, exon 2 
appeared to be unaffected in the resistant lines, whereas 
exons 5 to 9, which encode the motif contributing to the 
catalytic phosphatase activity of PTEN [20], seemed to be 
consistently lost.
To interrogate the functional impact of the deletion 
of large regions of PTEN as observed in the TR cells, we 
investigated whether genomic copy losses were reflected 
in transcriptional levels. Due to the importance of exons 
5, 8 and 9 in the function and stability of PTEN, we 
quantified the expression of these regions, as well as the 
region encompassing exons 1 and 2, which was unaffected 
in resistance cells, as a control. Our results showed that 
the exons 1 and 2 had similar transcriptional levels across 
TR, control and parental (THP-1) lines, while we observed 
a significant decrease in the expression of the exons 5, 8 
Table 1: MEK inhibition reduces the proliferation of AML cells
Pedatric Cell line Cytogenetics Sequence Features PD0325901 AZD6244 MEK162 GSK1120212 CI1040 TAK733 AS703026 Ara-C Daunorubicin Etoposide
MV-4-11 MLL-AF4 FLT3-ITD 0.17** 0.41* 0.33** 0.003*** 6.9 0.089** 0.41** 1.6 0.048 0.056
THP-1 MLL-AF9 TP53(R174fs*3), NRAS 
(G12D)
















NRAS (G13V) 0.24* 2.9 2.1 0.14* 4.8 0.25* 0.42* 2.6 0.057 3.4
Kasumi-1 t (8;21)(q22; 
q22)
RUNX1-CBFA2T1; 
c-KIT mut (N822K), 
TP53 (R248Q)
0.2 1.7 1.1 0 004 6.5 0.051 0.31 0.15 0.028 0.53
M-07e t (11;21)(p11; 
p13)
CREBBP (Q2208H) 0.11 1.1 0.34 0.006 4.8 0.038 0.08 0.033 0.0069 0.18
Adult ME1 CBFB-MYH11 0.003 0.022 0.037 0.00004 0.55 0.005 0.08 0.41 0.36 18
HL-60 MLL-AF6 CDKN2A (R80* and 
P135L), NRAS (Q61L), 
t (6,11)(q27; q23)
0.001 0.12 0.02 0.001 0.73 0.001 0.007 0.64 0.02 1.3








JAK2 (V617F), TP53 
(M133K), CDKN2A 
(M1_*157del)
>20 >20 >20 >20 >20 >20 >20 0.085 0.12 1.6
OCI-AML3 Hyperdiploid 
(+1, +5, +8, 
der (1) t(1;18)






0.008 0.07 0.04 9.20E-05 1.1 0.004 0.02 >20 0.019 0.47
Median 
all
0.11 0.3 0.33 0.003 2.2 0.038 0.08 0.445 0.048 1.3
IC50 is defined as the concentration of drug that reduces cell viability by 50%, calculated by non-linear regression. Median all is calculated excluding those values >20 uM where an exact 
IC50 could not be established.
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and 9 in the TR cells (Figure 2B). Moreover, PTEN levels, 
measured by immunoblot with an antibody specific to the 
C-terminal epitope, paralleled our qPCR results where 
PTEN levels were barely detected in the resistant cells, 
but were consistent and detectable in both parental cells 
and control cells (Figure 2C). These results show that the 
alterations in PTEN were perpetuated at both the transcript 
and protein levels.
Introduction of truncated PTEN in parental 
THP-1 cells results in MEK inhibitor resistance
Although PTEN loss has been suggested to play a 
role in drug resistance, there has not been any evidence 
to show the direct link between PTEN loss and drug 
resistance, particularly in AML, to our knowledge. To 
investigate whether loss of functional PTEN directly 
Table 2: Combination index between MEK inhibitors and conventional chemotherapeutic compounds
Cell line Drug A Drug B Combination index
Cytarabine 0.34 +++
AS703026 Daunorubicin 0.31 +++
Etoposide >1.1 -
Cytarabine 0.49 +++
CMK AZD6244 Daunorubicin <0.01 +++
Etoposide 0.6 +++
Cytarabine 0.32 +++
GSK1120212 Daunorubicin 0.14 +++
Etoposide >1.1 -
Cytarabine >1.1 -
AS703026 Daunorubicin >1.1 -
Etoposide >1.1 -
Cytarabine 0.24 +++
Kasumi1 AZD6244 Daunorubicin 0.96 ±
Etoposide 0.24 +++
Cytarabine >1.1 -
GSK1120212 Daunorubicin >1.1 -
Etoposide >1.1 -
Cytarabine 0.85 ++
AS703026 Daunorubicin 0.95 ±
Etoposide 1.1 ±
Cytarabine 0.42 +++
MV-4-11 AZD6244 Daunorubicin 0.47 +++
Etoposide 0.52 +++
Cytarabine >1.1 -
GSK1120212 Daunorubicin 0.82 ++
Etoposide >1.1 -
Cytarabine 0.64 +++
AS703026 Daunorubicin 0.67 +++
Etoposide >1.1 -
Cytarabine 0.36 +++
THP-1 AZD6244 Daunorubicin 0.43 +++
Etoposide 0.51 +++
Cytarabine >1.1 -
GSK1120212 Daunorubicin >1.1 -
Etoposide >1.1 -
Combination index was calculated from the ED50 using Chou-Talalay analysis in the CalcuSyn software; -, antagonism 
(>1.1); ±, additive (0.9–1.1); ++, moderate synergism (0.7–0.9); +++, synergism (0.3–0.7).
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contributes to resistance to MEKi, we used CRISPR/
Cas9 technology to introduce the functional loss of 
PTEN that we observed in resistance cells into parental 
(and therefore MEKi-sensitive) THP-1 cells. Using a 
ribonuclear protein (RNP) complex comprised of each of 
3 gRNAs that targets the exon 5 of PTEN (gP1, gP2, gP3), 
a fluorophore-labelled scaffolding RNA (tracrRNA) and a 
recombinant Cas9 protein, we introduced mutations at the 
locus that encodes the exon 5 of PTEN. These mutations 
resulted in a frameshift in the translation of the protein, 
as described previously [26], resulting in abrogation 
of the core catalytic motif in PTEN (Supplementary 
Figure 3A). An RNP complex using a gRNA that targets 
a gene desert region (gN) was included as a control for 
CRISPR. The 3 PTEN-targeting gRNAs were tested using 
a T7 endonuclease I assay, and all were proven to be able 
to introduce mutations into the designated locus in cells 
named P1, P2, P3 (Supplementary Figure 3B, 3C). Cells 
CRISPRed with gN (N) did not show any specific cleavage 
at this locus (Supplementary Figure 3C). Interestingly, 
CRISPRed cells (P1, P2, P3 and N) were viable when we 
expanded each of them 24 h post transfection in culture to 
a density of 106 cells/ml. Further T7 endonuclease I assays 
on P1, P2, P3, N and THP-1 cells revealed that mutations 
at the PTEN locus were retained, and THP-1 and N cells 
were not digested by T7, indicating that N cells share 
the same genomic sequence as the parental cells at the 
exon 5 of PTEN (Figure 3A). These results were further 
supported by Western blots, where THP-1 and N cells 
had comparable levels of PTEN (Figure 3B). In contrast, 
PTEN was undetectable in P1, P2 and P3 cells, and in a 
previously established resistant line (TR) (Figure 3B). We 
then measured IC50 of P1, P2, P3, and N cells, along with 
the THP-1 cells and TR cells, in the presence of AZD6244. 
We found that the N cells had a similar IC50 to THP-1 cells 
(IC50~0.2 uM) while P1, P2, and P3 all had IC50s similar to 
Figure 1: Copy number changes acquired during generation of MEKi-resistant phenotype. Copy number variation analysis 
of all TR populations revealed amplification and deletion events common to all samples which are known to be associated with cancer and/
or drug resistance. These events include deletion of PTEN, IRF4, and ELOLV2 and amplification of KRAS. TR copy changes are shown 
relative to DMSO controls. Each panel describes copy changes for the chromosome indicated in the title bar. Circle size indicates the 
statistical significance of the difference in gene copies (Bonferroni-adjusted p-values); large circles represent p < 0.001, medium circles 
represent 0.001 < p < 0.05; and small circles represent p ≥ 0.05. Circle colour represents replicates.
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Figure 2: PTEN loss in TR cells. (A) Copy number changes of PTEN exons. Normalized depth (log) of each probe targeting PTEN 
(indicated by o and •) was obtained by targeted exome sequencing. Grey line indicates the average depth of the entire locus. Dots above 
and below the grey line indicate gain and loss in copy numbers, respectively, at the targeted locus. (B) qPCR analysis of PTEN expression. 
The transcriptional levels of the exon 1–2, exon 5 and exon 8–9 of PTEN were determined by qPCR and normalized to GUSB. (C) 
Representative western blot of PTEN levels in the parental cells (lane 1), control cells (2–5) and resistant cells (6-9). GAPDH (37 kD) was 
used as a loading control for each blot. Data are presented as mean and standard deviation. **p < 0.01 (t-test, two-tailed).
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TR cells (IC50 >20 uM) (Figure 3C). These results showed 
that the off-target effect of CRISPR had minimal impact 
on THP-1 sensitivity to AZD6244, and, for the first time, 
shows the direct contribution of functional PTEN loss to 
the establishment of MEKi resistance.
PTEN loss correlates with an increase in 
transcription and activation of CREB
It has reported that CREB is a direct target of 
PTEN where PTEN physically interacts with, and 
dephosphorylates CREB at Serine 133 [27]. Interestingly, 
cancerous cells have been shown to restore the CREB 
phosphorylation that is suppressed upon MEK inhibitor 
treatment [28]. Therefore, we speculated that loss 
of the functional domain of PTEN increases CREB 
phosphorylation (pCREB) in leukemic cells, thus 
promoting cell survival and MEKi resistance. To test this 
hypothesis, we measured the total CREB (tCREB) levels 
and pCREB levels (S133) in TR, control and parental 
(THP-1) cells. Our results showed that parental cells 
and control cells had comparably low levels of tCREB 
and pCREB, while resistant cells showed elevated levels 
of both tCREB and pCREB (Supplementary Figure 4). 
This result suggests that loss of the functional domains 
of PTEN, at least in part, gives rise to an increased 
phosphorylation of CREB at Ser133, which may promote 
MEKi resistance as previously reported (Figure 3D) [28].
DISCUSSION
An improved treatment strategy is desperately 
needed for pediatric AML due to the side effects of current 
chemotherapy regimens. The Ras/Raf/MEK/ERK1/2 
pathway plays an essential role in human cancers and 
its contribution in leukemogenesis has been supported 
by a high incidence of mutations identified in the RAS 
gene family, such as NRAS [29–31] and by inappropriate 
activation of the pathway. MEK inhibitors are small 
molecules that have shown promise in clinical trials. 
However, little is known about their therapeutic potential 
in treating pediatric AML or whether mutations in RAS 
gene family could predict sensitivity to MEK inhibitors. 
Therefore, we used seven MEK inhibitors that have been 
investigated in clinical trials and examined their efficacy 
against a panel of 11 AML cell lines, six of which were 
pediatric (Table 1).
Our data demonstrate that this response to MEK 
inhibitors is independent of RAS mutational status. THP-
1 cells (NRASG12D) exhibited nanomolar IC50s for six of 
the seven MEKi. In contrast, AML-193 cells (NRASG13V) 
exhibited nanomolar sensitivity to just four of the seven 
Figure 3: Truncated PTEN is associated with resistance to MEKi via increased activity of CREB. (A) T7 endonuclease I 
assay of the CRISPRed THP-1 lines (P1, P2, P3 and N). (B) Representative Western blot of PTEN (54 kD) in each of the CRISPRed lines 
(N, P1, P2, P3), parental THP-1 cells and TR cells. GAPDH (37 kD) was used as a loading control. (C) Sensitivity of CRISPRed lines to 
AZD6244. Four independent experiments were performed and the mean of each sample at a given AZD6244 concentration was plotted. 
(D) Representative Western blot of pCREB and tCREB in the parental cells, control cells (1–4) and resistant cells (5–8). GAPDH (37 kD) 
was used as a loading control for each blot.
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MEKi. However, other cell lines such as MV-4-11 and 
OCI-AML3 that do not express a RAS mutation exhibit 
nanomolar IC50 values in six of the seven MEKi. This 
resistance may be explained by other oncogenic events 
in AML that drive Ras pathway activation such as FLT3-
ITD mutations. Indeed, MV-4-11 possesses this mutation. 
This observation has been supported by extensive clinical 
studies in solid tumours such as melanoma where the 
presence of Ras/Raf mutations did not elicit a uniform 
response and the variations were considered to be a result 
of co-occurring mutations [32, 33]. A recent study with 
AZD6244 in AML, however, showed that no patient with 
FLT3-ITD responded to treatment, whilst 17% of FLT3-
WT patients exhibited a response [13]. Taken together, 
these data indicate that the sensitivity to MEKi is not 
likely to be easily stratified according to a single mutation, 
including Ras or Raf mutations.
Interestingly, two cell lines (CMK and HEL) 
exhibited overt intrinsic resistance to MEKi with IC50 
above 20 µM (Table 1). These cell lines share the common 
element of a mutation in the JAK/STAT pathway and a 
p53M133K mutation. CMK cells express a JAK3A572V 
mutation and HEL express the well-characterized 
JAK2V617F mutation. Whilst numerous reports suggest 
activation of the PI3K/AKT pathway may elicit resistance 
to MEKi due to the nature of cross-talk between these two 
signaling pathways [34], the role of JAK/STAT pathway 
activation has not been extensively explored. Future 
studies investigating the functional influence of JAK/STAT 
signaling on MEKi sensitivity may have an important 
clinical impact for classifying patients who are unlikely 
to respond to MEKi monotherapy, or those where addition 
of a JAK inhibitor, such as ruxolitinib or pacritinib, may 
prove beneficial.
Despite the maintenance of a common structural 
backbone in all MEK inhibitors, a range of anti-
proliferative efficacy was observed, suggesting that a 
subset of AML cells are likely to require co-treatment 
with a second compound to induce complete population 
death. This hypothesis has been supported by in 
vitro studies and clinical trials of MEKi [35, 36]. We 
showed that combinations of MEKi with the cytotoxic 
agents, cytarabine and daunorubicin - currently used 
in chemotherapy, appeared to be overall synergistic. 
However, combinations with etoposide varied depending 
on the MEKi and the cell line (Table 2). It should be noted 
that all past and current clinical trials investigating the 
use of MEKi in AML have been in adults and, as such, 
the preclinical data presented here provide a rationale for 
investigating the use of chemotherapy supplemented with 
MEKi in pediatric AML patients.
Increasing amounts of effort have been spent on 
exploring how cancer cells acquire resistance to MEK 
inhibitors. We attempted to investigate the genetic 
attributes of MEKi resistance. After establishment of 
MEKi resistance in independent populations of an AML 
cell line we observed only one universally occurring 
mutation – copy loss of a functional domain in PTEN 
(Figure 1). No other acquired point mutations or copy 
changes (Supplementary File 2) in the targeted exome 
panel were observed in all resistant replicates compared 
to the control replicates. This mutation appeared to be 
clonally dominant suggesting that it was able to confer a 
significant survival advantage on these cells while being 
challenged with a MEKi and also that it likely occurred 
prior to the other acquired mutations that we observed. 
Furthermore, we were able to demonstrate that abrogation 
of PTEN function by introducing what is effectively the 
same acquired mutation into the parental, MEKi-sensitive 
cell line was sufficient to confer MEKi resistance in these 
cells. It is possible that other mutations were universally 
acquired in the resistant replicates in other regions of 
the genome as we interrogated only the genes present 
in the targeted exome panel. However, the evidence that 
the single CRISPRed PTEN mutation was able to confer 
the same level of acquired MEKi resistance on the parental 
cells is highly suggestive that this single event is sufficient 
for resistance given the genetic background of this AML 
cell line. Similarly, when we treated these cells with other 
MEKi, we again observed a lack of sensitivity to these 
agents suggesting that there is a common mechanism of 
resistance (Table 3). Interestingly, PTEN loss is associated 
with resistance to MEK inhibitors in a variety of cancers, 
and in fact may be a common mechanism for conferring 
resistance to other therapies such as PI3Kβ and BRAF 
inhibitors and immunotherapy [21, 22, 37–39].
In addition to PTEN loss, we observed some 
additional universal copy changes (Figure 1). Because 
these copy change events appear to be present in a smaller 
proportion of cells than the PTEN loss we believe these 
changes occurred subsequent to the PTEN event and may 
be secondary to acquired MEKi resistance. For example, 
we observed amplification of KRAS. While the role of 
mutated KRAS in cancer and therapy resistance has been 
widely described, KRAS gene amplification appears to 
be associated with tumour phenotype rather than with 
the acquisition of therapy resistance [40]. Loss of IRF4, 
an event we observed in all of our resistant replicates, is 
reported to be associated with leukemic progression in 
both lymphoid and myeloid cells, which is consistent with 
the tumour suppression function of this protein [41–43]. 
Finally, we observed universal loss of ELOVL2 in our 
resistant replicates. While this gene has been implicated 
in cancer [44, 46] it is unclear what role this event may 
play in either leukemia or therapy resistance.
Interestingly, three resistant replicates acquired a 
single nucleotide variant in NTRK2 at the same position 
(chr9:87570296) potentially causing a G>D substitution 
at amino acid 679 in the protein (Supplementary Figure 
2). This mutation has not been previously reported so 
it is unclear what affect, if any, it may have on protein 
function. One study found that NTRK2 activation 
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cooperates with PTEN loss in T-ALL [45, 47] so it is 
tantalizing to hypothesize that this mutation acts in a 
similar way in these cells providing them with yet another 
survival advantage. Indeed, the observed variant is only 
three residues from the active site of this enzyme and is 
proximal to autophosphorylated tyrosine residues (based 
on a mapping of UniProt entry Q16620 to protein structure 
1WWB.X) [39].
While PTEN loss has been previously implicated in 
resistance to a number of other therapeutic agents, this is 
the first time that it has been shown directly and in AML. 
We were also able to demonstrate that MEKi synergize 
with other chemotherapeutic compounds, at least in some 
cases, so, while MEKi utility in AML is clearly limited 
by the development of resistant subclones, combination 
therapy may be a viable strategy to mitigate this effect. 
In addition, establishment of PTEN status at diagnosis, 
as well as the status of other events known to contribute 
to MEK signaling-independent growth (e. g., FLT3-
ITD) may identify patients that are unlikely to respond 
to MEKi therapy and thus inform alternative treatment 
approaches.
MATERIALS AND METHODS
Cell culture and reagents
All human AML cell lines were purchased directly 
from recognized repositories; Kasumi-1, MV-4-11, CMK, 
AML-193, M-07e, HL-60, ML-2, OCI-AML3, ME-1 and 
HEL from DSMZ (Braunschweig, Germany) and THP-1 
from ATCC (Manassas, USA).
AZD6244, PD0325901, GSK1120212, CI-1040, 
TAK-733, AS703026, MEK162, cytarabine (cytosine 
arabinoside), daunorubicin hydrochloride (daunorubicin) 
and etoposide were obtained from Selleck chemicals 
(Houston, USA). ARRY-162 was purchased from 
ChemieTek (Indiana, USA). All compounds were 
dissolved in DMSO and stored at –20° C.
Cell proliferation, cell cycle and apoptosis assays
Human AML cell lines (2 × 104 cells/well) were 
seeded in a 96-well plate with appropriate factors and 
the indicated concentrations of compound for 96 hours. 
Assays were plated in quadruplicate and repeated at least 
three times. Proliferation was assessed using a resazurin 
reduction assay (CellTiter-Blue™, Promega, WI, USA). 
The concentration of compound that reduced cell viability 
by 50% (IC50) was determined using non-linear regression 
with variable slope after normalising fluorescence to 
untreated cellular controls. For combination assays, cells 
were treated with fixed ratio concentrations of one MEKi 
(GSK1120212, AS703026 or AZD6244) in combination 
with one cytotoxic compound (cytarabine, daunorubicin 
or etoposide) for 96 h. For cell cycle analysis, cells (2 ×105 
cells/mL) were seeded in 96-well plates with appropriate 
factors and the indicated compound concentrations for 96 
h. Assayed cells were fixed in 100 µL 70% ethanol in 
PBS at 4° C. Cells were washed in PBS then incubated 
with 40 mg/mL propidium iodide (PI; Sigma Aldrich, 
MO, USA) and 250 mg/mL RNase (Sigma Aldrich) for 
30 minutes at 37° C. Apoptosis was measured using the 
annexin-V FITC apoptosis detection kit according to 
manufacturer’s instructions (BD Biosciences). AML cell 
lines were seeded at 2 × 105 cells/mL and treated with 
indicated concentrations of compound for 96 h. Samples 
were stained for annexin-V FITC (BioLegend, CA, USA) 
and PI. Samples were analyzed on an LSRII FortessaTM 
flow cytometer (BD Biosciences, NJ, USA), data were 
acquired using the BD FACSDiva software and analysed 
with FlowJo software.
Immunoblotting
Cells were washed and lysed as previously described 
[23]. Total protein (10µg) was separated by SDS-PAGE 
and transferred onto nitrocellulose membranes (GE 
Healthcare, Buckinghamshire, England). Antibodies used 
for immunoblotting included anti-pMEK1/2(Ser217/221), 
-MEK1/2 total, -ERK1/2(Thr202/Tyr204), -ERK1/2 total, 
PARP, -pAKT (S473), -AKT, pCREB (S133) and CREB 
(Cell Signalling Technology, Inc., MA, USA) and anti-
GAPDH (Millipore, USA). Membranes were incubated 
with IRDye® 680LT or IRDye 800CW conjugated 
secondary antibodies and protein-antibody complexes 
visualized as previously described [48].
Development of MEKi-resistant THP-1 cells
THP-1 cells with resistance to AZD6244 (referred 
to as TR) were developed by culturing THP-1 cells in the 
presence of increasing concentrations of the compound 
(with ≤0.1% DMSO) until confluent growth was sustained 
in 20 times the IC50 (>10 µM). Resistance was confirmed 
by incubating cells in drug free media for a minimum of 
Table 3: MEK inhibitor resistance in THP-1 AML cells
Cell line AZD6244 MEK162 GSK1120212 AS703026
Parental 0.3 0.43 0.08 0.23
TR >20 >20 >20 >20
Values shown are IC50s, defined as the concentration of drug that reduces cE by non-linear regression. Values >20 uM 
indicate where an exact IC50 coulc Ara-C; cytarabine arabinoside.
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one week followed by CTB assay with drug concentrations 
up to 20 µM. Subsequent experiments using the TR lines 
were carried out on cells incubated in drug free media for 
a minimum of one week. The resistance development was 
replicated 8 independent times and paired with DMSO 
treated controls to establish background mutation rate 
occurring over time with culture.
Exome sequencing
Libraries were prepared using the Nugen Ovation 
Target Enrichment System and 2 × 150 bp paired end 
sequencing was performed on the Illumina MiSeq v2 
at the Monash Health Translation Precinct Medical 
Genomics Facility. The Ovation Cancer Panel 2.0 Target 
Enrichment Probes panel was used to perform targeted 
exome sequencing of known cancer genes to mean 
depth of coverage of 53× (range 47–67×) according to 
manufacturer’s specifications. Briefly, 500ng of DNA from 
8 resistant cell lines and the paired DMSO controls was 
sheared, ligated to adapter probe and purified. Libraries 
were pooled for enrichment at equimolar ratios and 15 pM 
of a single pool was used for clustering. The total run 
yield was 4.3G encompassing a total of 14,319,766 reads. 
The 1% PhiX spike in parameters were rated excellent 
for having an error rate of 0.27% and phasing/prephasing 
of 0.092/0.051. Reads were aligned to the hs37d5 human 
reference genome using NovoAlign followed by duplicate 
read marking and base quality recalibration according to 
GATK best practices. Single nucleotide variants and small 
indels were called using mutect2 [49]. To investigate copy 
number variation, bedtools 2.26.0(CITE: https://academic.
oup.com/bioinformatics/article/26/6/841/244688/BEDTools-
a-flexible-suite-of-utilities-for) was used to calculate mean 
coverage depth per exon in each sample. Exons with group 
mean coverage below 20 reads in both control and treated 
groups were excluded from the analyses to reduce noise. 
Read depths in each sample were normalized by total library 
size, and control and treated normalized exon read depths 
compared using a Student’s t-test (p-values adjusted using 
the Bonferroni correction) to identify alterations in copy 
number.
qPCR validation of PTEN loss by transcription 
quantification
RNA (100ng) was reverse transcribed in a 20 ul 
reaction using SensiFast cDNA synthesis kit (Bioline, 
USA). The cDNA was diluted 1 in 10 and 4 ul was 
used in qPCR with 1 x SYBR green MasterMix (Life 
Technologies, Thermofisher Scientific, USA) and a pair of 
gene-specific primers (Supplementary Table 1). Cycling 
was performed using ViiA 7 thermocycler (Applied 
Biosystems, USA) with its default cycling conditions. 
GUSB was used as a housekeeper to quantify the PTEN 
expression in samples. Analysis was performed using the 
2−∆∆CT method.
Introducing mutations in the exon 5 of PTEN
CRISPR was performed using Ribonuclear protein 
(RNP) complex system to introduce mutations in the 
exon 5 of PTEN, which encodes the catalytic core motif 
of the protein [20]. Guide RNAs (gRNAs) were designed 
using a web designing tool (http://portals.broadinstitute.
org/gpp/public/analysis-tools/sgrna-design). A total of 3 
gRNAs (gP1, gP2, gP3) that target the bases before the 
core motif-encoding region were selected based on their 
target efficiency score (Supplementary Table 2). Each 
of the 3 gRNAs was then complexed with an ATTO-
550 labelled scaffolding RNA (tracrRNA) (IDT, USA) 
and a recombinant Cas9 protein (NEB, USA) following 
manufacturer’s instructions. The RNP complexes (10nM) 
were transfected into THP-1 cells using RNAiMax (Life 
Technologies, USA); and the cells were cultured at 37° C 
with 5% CO2. A CRISPR experiment using a negative 
control gRNA (N) (IDT, USA) was also performed 
along with other CRISPR experiments. Genome editing 
efficiency was measured 48 h post-transfection.
Measurement of genome-editing efficiency
Genome editing efficiency was measured using 
T7 endonuclease I according to the manufacturer’s 
instructions (NEB, USA). Briefly, genomic DNA (gDNA) 
was extracted using Genomic DNA isolation kit (Bioline, 
USA). A pair of primers were used in the presence of 
the Platinum Taq DNA Polymerase High Fidelity (Life 
Technologies, USA) to amplify a 595 bp region including 
357 bp of the intron 4 that is sitting immediately upstream 
of the exon 5 and 238 bp of the exon 5 from 200ng of 
gDNA (Supplementary Table 1). Cycling was performed 
using Eppendorff PCR thermocycler for a total of 35 
cycles. Each cycle started with denaturing at 94° C for 
15s, followed by annealing at 60° C for 30s and an 
extension at 68° C for 30s. The PCR products were then 
ramped following the manufacturer’s instruction (IDT, 
USA) and digested using 10 units of T7 endonuclease I 
at 37° C for 15 min. Fragmentation was separated by gel 
electrophoresis and visualized by Quantum ST4 Xpress 
system (Montreal Biotech, USA).
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